Clene Inc. (CLNN) stock
CLNNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.92−0.08 (-2.00%)
Close on Nov 13, 2026Market cap $50.37MP/E –Yield –
Clene gross margin
Gross margin is gross profit as a percentage of revenue.
Clene's gross margin for the twelve months ending Sep 30, 2026 was 68.5%. For fiscal 2025 it was 78.5%, against 79.5% the year before. The highest annual figure on record is 94.5% in fiscal 2022.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 78.5% | −1.0 |
| FY2024 | Dec 31, 2024 | 79.5% | −2.0 |
| FY2023 | Dec 31, 2023 | 81.5% | −13.0 |
| FY2022 | Dec 31, 2022 | 94.5% | +34.5 |
| FY2021 | Dec 31, 2021 | 60.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 71.4% | −28.6 |
| Q2 FY2026 | Jun 30, 2026 | 60.0% | −40.0 |
| Q1 FY2026 | Mar 31, 2026 | 100.0% | +24.7 |
| Q4 FY2025 | Dec 31, 2025 | 70.1% | −10.1 |
| Q3 FY2025 | Sep 30, 2025 | 100.0% | +20.7 |
| Q2 FY2025 | Jun 30, 2025 | 100.0% | +19.8 |
| Q1 FY2025 | Mar 31, 2025 | 75.3% | −2.8 |
| Q4 FY2024 | Dec 31, 2024 | 80.2% | +2.6 |
| Q3 FY2024 | Sep 30, 2024 | 79.3% | −9.6 |
| Q2 FY2024 | Jun 30, 2024 | 80.2% | +4.8 |
| Q1 FY2024 | Mar 31, 2024 | 78.1% | −17.2 |
| Q4 FY2023 | Dec 31, 2023 | 77.6% | −22.4 |
| Q3 FY2023 | Sep 30, 2023 | 88.9% | −11.1 |
| Q2 FY2023 | Jun 30, 2023 | 75.5% | −11.8 |
| Q1 FY2023 | Mar 31, 2023 | 95.3% | +271.4 |
| Q2 FY2022 | Jun 30, 2022 | 100.0% | +0.0 |
| Q1 FY2022 | Mar 31, 2022 | 100.0% | – |
| Q3 FY2021 | Sep 30, 2021 | 87.3% | – |
| Q2 FY2021 | Jun 30, 2021 | -176.1% | – |
| Q3 FY2020 | Sep 30, 2020 | 100.0% | – |
See a number that looks wrong?